Debamestrocel is a Cell Therapy owned by BrainStorm Cell Therapeutics, and is involved in 8 clinical trials, of which 6 were completed, 1 is ongoing, and 1 is planned.

Stem cells secrete nerve-growth factors such as glial cells derived neurotrophic factor which protect existing motor neurons, promote motor neuron growth, and re-establish nerve-muscle interaction. The involved mechanism induce sprouting of nerve endings, stimulate nerve-muscle interaction and promote recovery of cell damage. The stem cell therapy candidate exhibit therapeutic intervention by promoting the rapid recovery of damage by forming cells for tissue regeneration and repair.

The revenue for Debamestrocel is expected to reach a total of $2.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Debamestrocel NPV Report.

Debamestrocel was originated by Tel Aviv University and is currently owned by BrainStorm Cell Therapeutics.

Debamestrocel Overview

Debamestrocel (NurOwn) is under development for the treatment of neurodegenerative diseases such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (primary and secondary sclerosis), Parkinson’s disease (PD), Huntington's disease, peripheral nerve injury, Coronavirus Disease 2019 (COVID-19), acute respiratory distress syndrome and autism spectrum disorder. The therapy is administered by intramuscular and intrathecal routes. NurOwn is an autologous, adult stem cell therapy developed based on a differentiation method which reprograms bone marrow-derived mesenchymal stem cells (MSC) into highly specialized, neuron-supporting cells. It is developed based on NurOwn cell therapy platform.

BrainStorm Cell Therapeutics Overview

BrainStorm Cell Therapeutics, formerly Golden Hand Resources Inc, is a biotechnology company which develops autologous stem cell therapies for neurodegenerative diseases. Its pipeline mesenchymal stem cell products are being developed based on cell therapy platform NurOwn, customized for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, parkinson’s disease, huntington’s disease, autism spectrum disorder, peripheral nerve injury and other indications. Its proprietary technology NurOwn induces mesenchymal stem cells to secrete high levels of neurotrophic factors to promote the survival of neurons. The company has operations in the US and Israel. BrainStorm Cell Therapeutics is headquartered in New York, the US.

The operating loss of the company was US$24.5 million in FY2021, compared to an operating loss of US$31.7 million in FY2020. The net loss of the company was US$24.5 million in FY2021, compared to a net loss of US$31.8 million in FY2020.

Quick View – Debamestrocel

Report Segments
  • Innovator
Drug Name
  • Debamestrocel
Administration Pathway
  • Intramuscular
  • Intrathecal
Therapeutic Areas
  • Central Nervous System
  • Infectious Disease
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.